TrialClinical and experimental immunology2015

Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.

H B Niebur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.